

We invest in extraordinary people: People more often than not prove instrumental in determining the success of a young enterprise.
We are focused and highly selective: We work with a limited set of opportunities in the belief that our involvement can increase the probability of success for our portfolio companies.
We are early-stage investors: We have plenty of experience investing across the financing lifecycle of healthcare companies, but most commonly invest in young organizations. We understand and are comfortable assessing unproven technology and working through the challenges of scaling organizations from the earliest stages.
We expect a well conceived, coherent and capital efficient business plan: Building healthcare technology companies can be capital intensive, but we're particularly focused on models supported by the measured deployment and consumption of resources to achieve significant milestones.
We are well capitalized: We have more than $400 million committed across our four funds from leading institutions, families and individuals. Part of this capital is our own, and we try to think of it all that way. We will participate in financings as small as $1 million, but have the capacity to invest up to $15 million in a company over time.
We maintain a vast network of industry relationships and resources: Building companies is a collaborative process - diverse skills and experience, a strong capital base, and good minds all add strength to our companies. Our relationships with seasoned CEOs and industry executives, technical experts, service providers and co-investors serve us and our companies well at all stages of the process.
| "Aberdare's evaluations are focused and thorough. They have high-level, sophisticated resources that dig deep, ask the hard questions and then provide informed feedback. You know where you stand quickly... I think this is rare." - Steve Mento, President & CEO, Conatus Pharmaceuticals |
| "As a group, they are aware of what's happening at our company and have consistently proactively and reactively helped solve problems – and that is unique. Usually with a venture firm you have one contact; with Aberdare the entire team is part of your effort." - Earl Fender, CEO, VertiFlex |
| "Aberdare digs into the company's space in the world and the issues it faces as it tries to become a presence in that space and they are exceptionally thoughtful about setting company direction and dealing with issues along the way." - Pat Mahaffy, President & CEO, Clovis Oncology |